Bioventus LLC12.01.15
Durham, N.C.-based Bioventus LLC, an orthobiologic solutions company, has acquired BioStructures LLC, a proprietary developer and marketer of bioresorbable bone graft products for a broad range of spinal and orthopaedic surgical applications. The agreement includes the entire portfolio of products as well as its research and development pipeline. In addition, employees of BioStructures will be given offers to join Bioventus. Terms of the acquisition were not disclosed.
The BioStructures product portfolio includes synthetic, allograft, collagen, and demineralized bone matrix (DBM) solutions for surgeons. Its signature products are: Interface Bioactive Bonegraft, a synthetic graft used to repair osseous defects, and Signafuse Bioactive Bonegraft Putty comprised of a bi-phasic mineral composite combined with the company’s patented bioactive glass and resorbable polymer carrier.
“The acquisition of BioStructures aligns with our strategy to be a leader in orthobiologics, building on the launch of the Bioventus Surgical business with the OsteoAMP acquisition in 2014, and our longer term development of the next generation BMP,” said Tony Bihl, CEO of Bioventus. “This now gives Bioventus a broad offering of bone grafting solutions backed by clinical and technical data to benefit patients, surgeons, and hospitals.”
“This is a great event for BioStructures, Bioventus, our customers and our employees. We believe the combination of our product offerings will result in a truly unique and robust portfolio benefiting patients, surgeons and hospitals not found in the market today,” said Russell Cook, BioStructures CEO. “This acquisition will continue to allow the culture of innovation, as well as advance the positive momentum we have built at BioStructures. We are happy to announce the transaction and look forward to the future with confidence and excitement.”
Bioventus will continue to work with the current network of distributors carrying the BioStructures product portfolio and expand that sales footprint to bring these solutions to more surgeons and hospitals throughout the United States.
The BioStructures product portfolio includes synthetic, allograft, collagen, and demineralized bone matrix (DBM) solutions for surgeons. Its signature products are: Interface Bioactive Bonegraft, a synthetic graft used to repair osseous defects, and Signafuse Bioactive Bonegraft Putty comprised of a bi-phasic mineral composite combined with the company’s patented bioactive glass and resorbable polymer carrier.
“The acquisition of BioStructures aligns with our strategy to be a leader in orthobiologics, building on the launch of the Bioventus Surgical business with the OsteoAMP acquisition in 2014, and our longer term development of the next generation BMP,” said Tony Bihl, CEO of Bioventus. “This now gives Bioventus a broad offering of bone grafting solutions backed by clinical and technical data to benefit patients, surgeons, and hospitals.”
“This is a great event for BioStructures, Bioventus, our customers and our employees. We believe the combination of our product offerings will result in a truly unique and robust portfolio benefiting patients, surgeons and hospitals not found in the market today,” said Russell Cook, BioStructures CEO. “This acquisition will continue to allow the culture of innovation, as well as advance the positive momentum we have built at BioStructures. We are happy to announce the transaction and look forward to the future with confidence and excitement.”
Bioventus will continue to work with the current network of distributors carrying the BioStructures product portfolio and expand that sales footprint to bring these solutions to more surgeons and hospitals throughout the United States.